National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia; School of Population and Global Health, University of Melbourne, Melbourne, Vic., Australia; Murdoch Children's Research Institute, Melbourne, Vic., Australia; Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA.
Addiction. 2014 Aug;109(8):1306-17. doi: 10.1111/add.12536. Epub 2014 Apr 14.
Release from prison is a high-risk period for mortality. We examined the impact of opioid substitution therapy (OST), for opioid dependence during and after incarceration, upon mortality post-release.
A cohort was formed of all opioid-dependent people who entered OST between 1985 and 2010 and who, following first OST entry, were released from prison at least once between 2000 and 2012. We linked data on OST history, court and prison records and deaths.
New South Wales (NSW), Australia.
A total of 16,453 people released from prison 60,161 times.
Crude mortality rates (CMRs) were calculated according to OST retention; multivariable Cox regressions for post-release periods were undertaken to examine the association between OST exposure (a time-dependent variable) and mortality post-release, for which covariates were updated per-release.
There were 100,978 person-years (PY) post-release; 1050 deaths occurred. Most received OST while incarcerated (76.5%); individuals were receiving OST in 51% of releases. Lowest post-release mortality was among those continuously retained in OST post-release CMR 4 weeks post-release = 6.4 per 1000 PY; 95% confidence interval (CI) = 5.2, 7.8, highest among those with no OST (CMR = 36.7 per 1000 PY; 95% CI = 28.8, 45.9). Multi-factorial models showed OST exposure in the 4 weeks post-release reduced hazard of death by 75% (adjusted hazard ratio 0.25; 95% CI = 0.12, 0.53); OST receipt in prison had a short-term protective effect that decayed quickly across time.
In New South Wales, Australia, opioid substitution therapy in prison and post-release appears to reduce mortality risk in the immediate post-release period.
出狱后是死亡率的高危期。我们研究了监禁期间和出狱后接受阿片类药物替代疗法(OST)治疗阿片类药物依赖对出狱后死亡率的影响。
我们组建了一个队列,该队列由所有在 1985 年至 2010 年期间接受 OST 的阿片类药物依赖者组成,他们在首次接受 OST 后,在 2000 年至 2012 年期间至少有一次从监狱获释。我们将 OST 历史、法庭和监狱记录以及死亡数据进行了关联。
澳大利亚新南威尔士州(NSW)。
共 16453 人在 60161 次出狱。
根据 OST 保留情况计算粗死亡率(CMR);对出狱后的时间段进行多变量 Cox 回归,以研究 OST 暴露(一个时变变量)与出狱后死亡率之间的关联,其中每个出狱时都会更新协变量。
共有 100978 人年(PY)出狱后;有 1050 人死亡。大多数人在监禁期间接受 OST(76.5%);51%的人在出狱时接受 OST。出狱后最低的死亡率是那些在出狱后继续接受 OST 的人,CMR 在 4 周后出狱时为 6.4/1000PY;95%置信区间(CI)为 5.2,7.8,最高的是那些没有 OST 的人,CMR 为 36.7/1000PY;95%CI 为 28.8,45.9。多因素模型显示,在出狱后的 4 周内接受 OST 治疗可使死亡风险降低 75%(调整后的危险比 0.25;95%CI 为 0.12,0.53);入狱期间接受 OST 治疗有短期的保护作用,但随着时间的推移迅速衰减。
在澳大利亚新南威尔士州,监禁期间和出狱后接受阿片类药物替代疗法似乎降低了出狱后即刻的死亡风险。